Table 1.
Variable information.
| Variable | Source |
|---|---|
| Patient Information | |
| Patient municipality | (4) |
| Age at diagnosis | (4) |
| CRCI Diseases | (2) |
| CRCI | (2) |
| SDI | (4) |
| Residence-Hospital distance | (4) |
| Pathology Information | |
| Biopsy date | (1) |
| Pathology Division | (1) |
| Extra-prostatic invasion | (1) |
| Patient’s Gleason score | (1) |
| Clinical T | (8) |
| Core extraction zone | (1) |
| Presence of tumorat core level | (1) |
| Core Gleason score | (1) |
| Number of sampled cores | (1) |
| Diagnostic Procedures | |
| Number of previous negative biopsies | (1), (2), (3) |
| First negative biopsy date | (1), (2), (3) |
| DRE | (1), (2), (3) |
| PSA | (1), (2), (3) |
| TRUS | (1), (2), (3) |
| CT/PET-CT | (2) |
| MRI | (2) |
| Bone Scintigraphy | (2) |
| Post-diagnosis Treatment | |
| Biopsy | (1) |
| Biopsy date | (1) |
| TURP | (1) |
| TURP date | (1) |
| Prostatectomy | (1) |
| Prostatectomy date | (1) |
| Post-prostatectomy Gleason score | (1) |
| Pathological TNM | (1) |
| Radiotherapy | (2), (3) |
| Hormonotherapy | (2), (3) |
| Follow-up Information | |
| Vital status | (4) |
| Cause of death | (5) |
| Date of death | (4) |
| End of follow-up date | (4) |
| Metastasis at follow-up | (2), (3), (8) |
| Metastasis date | (2), (3), (8) |
| Metastatic Prostate Cancer | (2), (3), (8) |
| Death Due to Prostate Cancer | (2), (3), (8) |
| Centralised Pathology Review: Slide Level | |
| Total core number | (6) |
| Slide quality | (6) |
| Positive core number | (6) |
| HGPIN | (6) |
| Chronic inflammation | (6) |
| Acute inflammation | (6) |
| Centralised Pathology Review: Core Level | |
| Length | (6) |
| Area | (6) |
| Tumour Length | (6) |
| Tumour Area | (6) |
| Primary Gleason | (6) |
| Secondary Gleason | (6) |
| Gleason 4 percentage | (6) |
| ISUP Group | (6) |
| Centralised Pathology Review: Focus Region Level | |
| Length | (6) |
| Area | (6) |
| Presence of tumor | (6) |
| Atrophy a | (6) |
| Inflammation a | (6) |
| Perineurial invasion a | (6) |
| Extra-prostatic extension a | (6) |
| Intraductal carcinoma a | (6) |
| Ductal carcinoma a | (6) |
| Poorly formed glands a | (6) |
| Cribriform pattern a | (6) |
| Stroma rich a | (6) |
| Atypical intraductal proliferation a | (6) |
| Mucinous a | (6) |
| Acinar a | (6) |
| Signet ring cell a | (6) |
| Sarcomatoid a | (6) |
| Pleomorphic giant cell a | (6) |
| PIN-like carcinoma giant cell a | (6) |
| Small cell a | (6) |
| Neuro-endocrine differentiation a | (6) |
| Gleason elements a | (6) |
| Molecular Data | |
| Availability of extracted tumorDNA | (7) |
| DNA methylation level of selected candidate genes | (7) |
CRCI, Charlson-Romano Comorbidity Index; SDI, Social Deprivation Index; DRE, Digital Rectal Examination; PSA, Prostate-Specific Antigen; TRUS, Transrectal Ultrasonography; CT, Computed Tomography; PET-CT, Positron Emission Tomography-Computed Tomography; MRI, Magnetic Resonance Imaging; TURP, Transurethral Resection of the Prostate; HGPIN, High- grade Prostatic Intraepithelial Neoplasia; ISUP, International Society of Urological Pathology; PIN, Prostatic Intraepithelial Neoplasia.
These variables are Boolean and indicate the presence or absence of something.
(1): pathology reports (2), out- and in-patient clinical summaries (3), clinical charts (4), demographic files (5), mortality records (6), centralized histopathological review (7), molecular analyses (8), derived variables combining the multiple sources.